Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference

SAN DIEGO–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and H. Lundbeck A/S (Lundbeck) today presented positive results from a Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer’s dementia at the 2022 Alzheimer’s Association International Conference. The double-blind, randomized, placebo-controlled trial of 345 male and female participants with a diagnosis of probable Alzheimer’s disease was designed to a
Click here to view original post